Wedbush raised the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $11 and keeps an Outperform rating on the shares. The firm notes that last week, the company completed an upsized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results